The human prepronociceptin (ppNoc) gene is located on chromosome 8p21, and several linkage studies have suggested that the susceptibility locus for schizophrenia is present in this chromosomal region. We investigated genetic variations in the promoter and coding regions of the ppNoc gene to determine if there may be an association between naturally occurring mutations and the manifestation of schizophrenia. Association analyses for the variations found were conducted between 87 unrelated schizophrenic patients and 100 healthy controls. Polymorphisms were found at both the Ϫ503 locus (G/A) in the promoter region and the 353 locus (Ala118Gly) in exon 3. Additionally, rare variants were identified at the Ϫ261 locus (A/G) in the promoter region, the 515 locus (Gln172Arg) in exon 3, and the 561 locus (G/A) in the untranslated region of exon 3. A significant difference was observed in allele frequency at the 353 locus between controls and patients with continuous-course schizophrenia (P ϭ 0.0237), and between patients with and without prominent negative symptoms (P ϭ 0.0201). However, neither difference was significant after Bonferroni correction. In addition, there were no significant differences in genotype and allele frequencies at either the Ϫ503 or 353 locus between the control group and patients with schizophrenia. These results suggest that ppNoc gene polymorphisms have no association with schizophrenia.
Introduction
The opioid receptor-like 1 (ORL1) receptor is most closely related to opioid receptors in structure and function (Mollereau et al. 1994) . Nociceptin (Noc), alias orphanin FQ (OFQ), consists of a 17 amino acid peptide that has recently been discovered as an endogenous agonist for ORL1 (Meunier et al. 1995; Reinscheid et al. 1995) . Noc/OFQ is derived from a larger precursor protein, prepronociceptin (ppNoc), whose sequence is similar to the opioid peptide precursors, and whose mRNA is mainly expressed in the brain (Mollereau et al. 1996; Nothacker et al. 1996; Houtani et al. 1996) . The human ppNoc gene is located on chromosome 8p21, which has previously been reported as a susceptibility locus for schizophrenia (Kendler et al. 1996; Kaufmann et al. 1998; Blouin et al. 1998) .
Similarities between the effects of opioids and the symptoms of psychotic illness led to a hypothesis that the opioids are involved in the pathophysiology of schizophrenia (Wiegant et al. 1992) . Noc/OFQ blocks opioid-induced supraspinal analgesia, and it may represent a functional antiopioid peptide (Mogil et al. 1996) . Pain insensitivity has been reported in off-medication patients with schizophrenia (Davis et al. 1979) . Noc/OFQ reduces the morphineinduced dopamine release and suppresses the metabolites released from the nucleus accumbens in rats (Di Giannuario et al. 1999) . Drugs directed at the central Noc/ OFQ receptors may represent an interesting approach to the treatment of ethanol and opiate abuse (Ciccocioppo et al. 2000) . ORL1 knockout mice are fertile, and show no significant anatomical defects, but they do display a significant rise in their auditory brainstem responses (ABRs) threshold (Nishi et al. 1997) . Abnormal ABRs have also been reported in schizophrenic patients (Lindstrome et al. 1987) . In addition, the ORL1-deficient mice exhibited increased long-term potentiation, without apparent changes in presynaptic or postsynaptic electrophysiological properties (Manabe et al. 1998 ). There have been no previous reports examining the association between polymorphisms in the ppNoc gene and schizophrenia.
In the present study, we investigated genetic variations in the promoter region and the coding region of the ppNoc gene, and conducted a case-control study to explore an association between the ppNoc gene and schizophrenia.
Subjects and methods

DNA samples
Informed written consent was obtained from subjects prior to the study according to research protocols approved by the ethics committee of Tsukuba University. A total of 87 schizophrenic patients were examined, consisting of 53 men (mean age 46.3 Ϯ 12.7 years; mean age at onset 25.7 Ϯ 7.6 years) and 34 women (mean age 47.3 Ϯ 16.3 years; mean age at onset 27.7 Ϯ 10.7 years) who matched the DSM-IV criteria for schizophrenia (American Psychiatric Association 1994). Patients were further divided into subtypes (18 paranoid, 28 disorganized, 4 catatonic, 28 residual, and 9 undifferentiated) and longitudinal courses (57 episodic, 23 continuous, 5 single episode, and 2 other or unspecified). Furthermore, 33 patients were categorized with prominent negative symptoms, defined by the DSM-IV criteria, and 39 patients with a family history in first-or second-degree relatives.
The controls consisted of 100 unrelated volunteers (30 men: mean age 32.1 Ϯ 11.4 years, and 70 women: mean age 43.1 Ϯ 12.0 years), who were hospital employees living in the same area as the patients. Each volunteer was interviewed by two psychiatrists in order to rule out subjects with a family history of mental illness. All of the patients and controls were ethnically Japanese.
Genomic DNA samples were prepared from whole blood collected in disodium ethylenediaminetetraacetic acid (EDTA; 3 mg/L) according to the sodium iodide method (DNA Extractor WB Kit, Wako Pure Chemical Industries, Osaka, Japan).
Polymerase chain reaction conditions
Six sets of polymerase chain reaction (PCR) primers were used to produce DNA fragments covering exons 2 and 3, which share an open reading frame, and the promoter region of the ppNoc gene (Table 1 ). The nucleotidesequence numbering used in this study was based on a previous report (Xie et al. 1999; Zaveri et al. 2000) and the GenBank sequence (accession number X97370). All primers were designed from sequences available in the GenBank database (accession numbers: AF100704, X97367, and X97368). The 5Ј-terminus of each primer was labeled with indodicarbocyanine fluorescent dye (Amersham Pharmacia Biotech, Uppsala, Sweden) for fluorescence-based single-strand conformational polymorphism (SSCP) analysis.
The reaction mixture contained 0.5 ng genomic DNA, 0.25µM of each primer, 0.2 mM of each deoxynucleotide triphosphate, 10mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , and 0.5U of Taq DNA polymerase (HotStarTaq, QIAGEN, Hilden, Germany) in a final volume of 25µl.
The amplification reaction was as follows: an initial 15min denaturation at 95°C, followed by 35 cycles of denaturation at 94°C for 30s, annealing at 58°C for 30 s, and extension at 72°C for 30s, with a final extension step of 72°C for 10 min (GeneAmp 9600, PE Applied Biosystems, Foster city, CA, USA).
PCR products were visualized by ethidium bromide staining under UV light after electrophoresis in 2% agarose gels.
SSCP analysis
All 187 samples in our study were analyzed by using SSCP. A DNA sequencer (ALF express, Amersham Pharmacia Biotech) with a short gel plate was used to perform fluorescence-based SSCP analysis. One microliter of PCR product was mixed with 14µl of loading solution containing 99.5% deionized formamide and 0.5% blue dextran. The PCR using allele-specific primers When restriction endonuclease was not commercially available, PCR using allele-specific primers was performed to confirm the single-nucleotide polymorphisms (SNPs). Two allele-specific forward primers (PN-E3D-FЈC and PN-E3D-FЈG) and PN-E3D-R (reverse primer) were used for an analysis of the Ala118Gly mutation at the nucleotide position 353 (C/G) polymorphism identified by SSCP analysis (Table 1 ). The human -actin gene was coamplified as the internal positive control using the forward ( -actin S: 5Ј-CAAGAGATGGCCACGGCTGCT) and reverse ( -actin A: 5Ј-TCCTTCTGCATCCTGTCGGCA) primers (GenBank accession number AF053356).
Statistical analysis
Deviation of genotype distribution as derived from the Hardy-Weinberg equilibrium equation was calculated using the chi-square test for goodness of fit. Association analysis was performed by Fisher's exact probability test (twosided). Bonferroni correction for multiple comparisons was carried out to exclude a type I error. Analysis of linkage disequilibrium between two given loci was performed using Associate (version 2.32) software in conjunction with linkage utility programs (Terwillinger and Otto 1994) .
Results
Five variants of the ppNoc gene were identified in 187 samples by using SSCP analysis, and were confirmed further by direct sequencing of the PCR products. These included nucleotide substitutions at the Ϫ503 locus (G/A) and at the Ϫ261 locus (A/G) in the promoter region, missense mutations Ala118Gly at nucleotide position 353 (C/G) and Gln172Arg at the 515 locus (A/G) in the coding region of exon 3, and a nucleotide substitution at the 561 locus (G/A) in the untranslated region of exon 3. These variants did not correspond to any SNPs reported previously in the GenBank database (accession number NT_007988.2). The nucleotide positions Ϫ503, Ϫ261, 353, 515, and 561 in our study correspond to 704727, 704485, 682271, 682108, and 682063, respectively, in the GenBank database.
There were no commercially available restriction enzymes for the Ϫ503 and 353 polymorphic sites. Three genotypes (GG, GA, and AA) at the Ϫ503 locus could be distinguished clearly by SSCP analysis as well as by PCR direct sequencing (Fig. 1) . Therefore, genotypes of all samples at that locus were determined by SSCP analysis. In contrast, we determined the genotypes at the 353 locus by using PCR with allele-specific primers (Fig. 2) , because we could distinguish them more clearly than with SSCP analysis.
The occurrence of mutations at the Ϫ261 (A/G), 515 (A/ G), and 561 (G/A) loci was rare in our samples. The transition from A to G at the Ϫ261 locus was found in only two controls and two schizophrenic patients, while the transition from A to G at the 515 locus was found in only one control. The transition from G to A at the 561 locus was found in only one control and one patient. All of these mutations were identified as heterozygous (Data not shown).
Distributions of all alleles at the Ϫ503 and 353 loci were consistent with the Hardy-Weinberg equilibrium equation Fig. 1 . Single-strand conformational polymorphism (SSCP) analysis and direct sequencing analysis of polymerase chain reaction (PCR) products generated using the PN-PU-F and PN-PU-R primer sets. The Ϫ503 (G/A) nucleotide substitution was detected by sequencing. Lanes 1, 2, and 3 indicate homozygous (GG), heterozygous (GA), and homozygous (AA) genotypes, respectively (P Ͼ 0.05). One allele of single-episode-course and other or unspecified-course at the 353 locus could not be tested due to the small sample size.
No significant differences in genotype or allele frequencies at either the Ϫ503 or 353 locus were found between controls and patients (Table 2 ). In contrast, there was a significant difference in allele frequencies of the 353 (C/G) variant between controls and patients falling into the continuous-course category, as well as between controls and patients with prominent negative symptoms ( Table 2) . These results indicate that the frequency of the 353 G allele in patients with continuous-course schizophrenia or patients with prominent negative symptoms was significantly higher than in controls. The difference was also significant between patients with and without continuous-course schizophrenia and between patients with and without prominent negative symptoms (Table 3) . In examining the frequency of the homozygous genotype (GG) versus the other genotypes with the C allele (CC ϩ CG) at the 353 locus, a significant difference was also found between the control group and patients with continuous-course schizophrenia (P ϭ 0.0111, odds ratio [95% confidence interval]: 10.32 [1.76-60.41]), and between controls and patients with prominent negative symptoms (P ϭ 0.0104, odds ratio: 8.75 [1.61-47.57] ). In addition, in the frequency analysis of the homozygous genotype (GG) versus the other genotypes with the A allele (GA ϩ AA) at the Ϫ503 locus, there was a significant difference between controls and patients with paranoid-type schizophrenia (P ϭ 0.0236, odds ratio: 7.64 [0.97-60.01]). However, no P-value differences were significant after Bonferroni correction for multiple comparisons. Furthermore, no significant differences between the controls and the patients with other subtypes, longitudinal course specifiers, or positive family history were found. A weak linkage disequilibrium was found, however, between the variants at the Ϫ503 (G/A) and 353 (C/G) loci in 187 samples (delta value ϭ 0.0549, P ϭ 0.000043). Fig. 2 . The 267-bp PCR product was generated using the PN-E3D-R and PN-E3D-FЈC (in lane C) or PN-E3D-FЈG (in lane G) primer sets. The 370-bp PCR product was coamplified using the human -actin S and -actin A primer set as an internal standard. The Ala118Gly mutation at the nucleotide position 353 (C/G) substitution was detected by direct sequencing analysis of PCR products generated using the PN-E3D-F and PN-E3D-R primer set. Shown here is the reverse sequencing. Samples 1, 2, and 3 indicate homozygous (CC), heterozygous (CG), and homozygous (GG) genotypes, respectively 
Discussion
Recently, 17 SNPs have been reported for the ppNoc gene in the GenBank database (accession number NT_007988.2). However, these polymorphic sites are located in the untranslated region (intron 1, intron 2, intron 3, and the untranslated region of exon 4). In the present study, we have newly identified two nucleotide substitutions in the promoter region, two missense mutations in exon 3, and one nucleotide substitution in the untranslated region of exon 3. It is also noteworthy that the variants at the Ϫ503 and 353 loci were highly polymorphic.
As there was no commercially available restriction enzyme for the 353 polymorphic site, we tried to identify the polymorphism by using PCR based on allele-specific primers, although this method may introduce errors. We used HotStarTaq Taq polymerase (QIAGEN) to minimize mismatching of primers, and also the -actin gene was coamplified as an internal positive control. Indeed, three genotypes (CC, CG, and GG) were distinguished clearly, as shown in Fig. 2 .
We further analyzed the association between the polymorphism at the Ϫ503 locus and clinical schizophrenia, including an analysis between diagnostic subtypes and course specifiers, but found no significant differences between controls and patients. Using the TFSEARCH database program [Akiyama: http://molsun1.cbrc.aist.go.jp/research/ db/TFSEARCH.html] to look for the putative consensus sequences of transcription factor binding sites, we found that the region of the Ϫ503 locus (G/A) did not correspond to any motifs relating to transcriptional regulation. Therefore, this polymorphism may not functionally influence the transcriptional activity of the ppNoc gene.
The ppNoc gene produces at least two bioactive peptides, Noc/OFQ and nocistatin. Nocistatin possesses antinociceptive activity, and has been shown to play an important role in the regulation of pain transmission, as well as in learning and memory processes in the central nervous system (Okuda-Ashitaka et al. 1998; OkudaAshitaka and Ito 2000) . As shown in Fig. 3 , the mutation site of Ala118Gly is represented in the amino acid sequence of nocistatin; however, it is not located in the carboxylterminal hexapeptide portion (122Glu-Gln-Lys-Gln-Leu127Gln) that is important for activity (Okuda-Ashitaka et al. 1998; Okuda-Ashitaka and Ito 2000) . The allele frequency of the missense mutation at the 353 locus was significantly higher in "treatment-refractory" patients with continuous-course schizophrenia and with prominent negative symptoms (P Ͻ 0.05). The observed P values, however, were not significant after Bonferroni correction.
We assume that the major shortcoming in this analysis was the small sample size; therefore, further study using a larger population will be necessary to confirm the relationship between the 353 (C/G) variant and the clinical characteristics of schizophrenia. In addition, it is possible that we could have missed a variant, because the sensitivity of SSCP analysis is probably not 100% (Jordanova et al. 1997) . In conclusion, our data suggest that the ppNoc gene polymorphisms have no association with schizophrenia or its clinical characteristics. 
